Asieris igang med uttesting av cevira i kina

Asieris melder at cevira vil bli testet som behandling for livmorhalskreft i Kina nå
Redigert 25.03.2020 kl 15:56 Du må logge inn for å svare

Det betyr store penger i kassen til pho

Den meldingen må du nesten linke til ASAP, hvis ikke driver du med falske opplysnigner og det er STRAFFBART.

Henger jo ikke på greip med hva du skriver i innlegget, rapportert.

note: Jeg er all in i photocure
25.03.2020 kl 15:33 1403

sokaratest skrev Se link over
Dette er tull.

"Cevira®, a photodynamic drug combination product for non-surgical treatment of cervical precancerous lesions, which is being developed by Yahong Pharmaceutical, will also start the China-US-Europe International Multi-Center III clinical trial, mainly for Chinese patients, in 2020."

sokaratest skrev Se link over
Trodde du var såpass at du hadde lært deg noen grunnleggende kanskje den engelske passer bedre

Nytt fra Asieris igår.

Finner den dessverre bare i et word dokument, Cevira er omtalt litt nedenfor.

Finnes også på kinesisk. [](

Asieris 24-03-2020

Yahong Pharmaceutical announces the completion of Series C financing to accelerate the development of the world's first innovative drug

Time: 2020-03-24

Shanghai, China, March 24, 2020-Yahong Pharmaceutical Technology Co., Ltd. ("Yahong Pharmaceutical") today announced the completion of Series C financing, raising hundreds of millions of yuan in capital, and the C + round of financing will also be completed in the near future. This round of financing was led by Yanyuan Innovation Capital, followed by investment institutions such as Interchina Venture Capital and Yifeng Capital. Round B investment institutions Beijing Longpan and Kaitai Capital continued to invest in this round through cooperative funds. The funds raised will be used to support the company's multiple independent research and development projects.

The key project of Yahong Pharmaceuticals APL-1202 is the national “Twelfth Five-Year Plan” and “Thirteenth Five-Year Plan for Major New Drug Creation Projects”. It is the world's first innovative drug for oral treatment of non-muscle invasive bladder cancer that has entered registered clinical development. At present, the standard drug treatment method for preventing recurrence of non-muscle invasive bladder cancer after surgery is bladder infusion chemotherapy or BCG. The whole process is very painful and the adverse reactions are serious. APL-1202, as a new oral antitumor mechanism, is convenient, painless, and harmless to the urethra. It will help patients avoid or delay the fate of total bladder resection. APL-1202 has completed the phase III clinical trial of all patients in China, and also completed the phase I clinical trial in the United States. The phase II clinical trial in the United States is about to start.

Cevira®, a photodynamic drug combination product for non-surgical treatment of cervical precancerous lesions, which is being developed by Yahong Pharmaceutical, will also start the China-US-Europe International Multi-Center III clinical trial, mainly for Chinese patients, in 2020. Cevira® is targeted to treat patients 18 years of age and older who have a histopathologically proven high-grade cervical squamous intraepithelial lesion (HSIL). The current standard treatment for these patients is surgery. The most common treatments include cervical circular resection (LEEP / LLETZ) and cold-knife cone resection (CKC). However, these surgical treatments have adverse reactions, including bleeding. , Infection, cervical organic damage caused by a series of subsequent effects on fertility, such as premature delivery, abortion and so on. Therefore, Cevira® will provide a new treatment option for Chinese and global patients, so that some patients can avoid the pain and side effects of surgical treatment, especially the risk of future pregnancy. Cevira® has also won the Fierce Life Science Innovation Award with the international reputation of the best medical device innovation award 2019.

Yahong Pharmaceutical's other research project APL-1501 also belongs to the country's "13th Five-Year Plan for Major New Drug Development". This project mainly focuses on the treatment of multi-drug resistant infections. Compared to traditional antibiotics, APL-1501 has a new antibacterial mechanism and has good bactericidal activity against broad-spectrum Gram-positive and negative drug-resistant bacteria. And it has shown good efficacy in animal models of systemic multidrug resistance infection. APL-1501 is of great significance in addressing the severe challenge of no drug treatment after multidrug resistance infections facing the world, especially in China. In addition to multiple independent research and development of new drug projects and exclusive technology platforms, Yahong Pharmaceutical also negotiates with many domestic and foreign biopharmaceutical companies to develop cooperation in China and overseas markets.

Dr. Pan Ke, co-founder and CEO of Yahong Pharmaceutical, said: "This Series C financing led by Yanyuan Innovation Capital has provided strong support for the subsequent development of Yahong Pharmaceutical, and we are very grateful to investors for their support. Recognition of Rainbow Pharmaceutical's R & D strategies, projects and technologies. After ten years of accumulation, 2020 will be a year of rapid development for Yahong Pharmaceutical, and many projects will soon complete clinical trials or apply for new drug certificates. Yahong Pharmaceutical will also embark on a new The journey from the R & D company to the pharmaceutical company integrating research, production and sales will bring innovative therapeutic drugs and better treatment methods to more patients as soon as possible. "

Yanyuan Innovation Capital has always been adhering to the concept of value investment. In recent years, it has vigorously deployed life and health, especially biomedicine, medical equipment and other sub-sectors. Liu Zeng, President of Yanyuan Innovation Capital, commented, "Yahong Pharmaceuticals has a rich product pipeline layout and unique technology platform, and has breakthrough potential in its focus on the field of urogenital tumors. We believe that Dr. Pan, led by Hong The team can fully combine the advantages of domestic and foreign technologies, talents, capital and markets to make Yahong Pharmaceutical into a leading pharmaceutical company at home and abroad. We are glad to participate in the growth of Yahong together. "

Since its establishment in 2010, Yahong Pharmaceutical has been adhering to the belief of "improving human health and making life more dignified", and is committed to becoming the most innovative and influential pharmaceutical company in the field of focus and respect and trust. Yahong Pharmaceutical's business is located in Shanghai, Beijing, Jiangsu Taizhou Medical City and the United States.At the same time, it has established a research and development center in Shanghai and has established an international professional R & D technical team, focusing on anti-tumor and related diseases of the urogenital system. Global innovative drug research and development. Yahong Pharmaceutical's previous rounds of A and B financing have been led by well-known venture capital institutions such as Taifu Capital and Beijing Longpan.

About Yahong Pharmaceutical

Yahong Pharmaceutical was established in March 2010 in China Medical City, Taizhou City, Jiangsu Province, and established a research and development center in Shanghai. It is a global innovative drug research and development company focusing on anti-tumor and related diseases of the urogenital system in China. Yahong Pharmaceutical is determined to become the most innovative and influential pharmaceutical company in the field of focus, most respectable and trustworthy. The company focused on the urogenital field and quickly established a leading position in this field and carried out a deep strategic layout. Yahong Pharmaceutical fully explores the global value of first-in-class new drugs with independent research and development and breakthrough therapeutic potential, while introducing new drugs that are already in the late stage of development overseas or have been launched into the Chinese market, improving product pipeline diversification and synergy, Quickly establish a leading position in the domestic market.

About Yanyuan Innovation Capital

Yanyuan Innovation Capital, formerly known as "Yanyuan Capital Group", was founded in June 2010. With the support of the Peking University Science and Technology Development Department, it is a high-tech enterprise jointly established by Peking University alumni who are engaged in venture capital investment and university technology achievement transformation. Investment and capital operation platform, currently has three major business segments of equity investment, securities investment, listed company cooperation and mergers and acquisitions reorganization. The headquarters is located in Beijing. It was established in Ningbo, Zhejiang in 2015, Hangzhou office in 2018, and Shanghai office in 2019. Close to 70 people. The overall management scale of venture capital funds, industrial funds, parent funds, and securities funds managed directly or indirectly by Yanyuan Innovation Capital has exceeded RMB 6 billion; 5 private equity fund managers have been registered, and more than 30 private equity funds have been registered Over 50 foreign investment projects, and more than 10 companies have been listed and declared to be listed in the past three years. The investment fields cover such industries as biomedicine, advanced manufacturing, and new-generation information technology. In 2019, there were 2 companies in the biomedical field in the invested companies listed on the science and technology board, of which Zeyu Pharmaceutical led by Yanyuan Innovation Capital was the first company in the science and technology board to declare and list on the fifth set of standards. Unprofitable biopharmaceutical company.

About Interchina Ventures

Shenzhen Guozhong Venture Capital Management Co., Ltd. is a private equity investment agency specializing in the management of venture capital investment trusts. Interstate Venture Capital advocates the investment concept of research first, combining investment with research. Guide the investment through in-depth research on the industry chain, focus on investment opportunities in strategic emerging industries, and focus on investing in outstanding companies in the three major areas of technological innovation, biomedical health, and TMT.

About Yifeng Capital

Yifeng Capita

Du får vise til et utdrag der det faktisk står at Cevira vil bli brukt som behandling i Kina nå, de er jo såvidt i gang med fase 3 studiet.
26.03.2020 kl 06:59 1053

Artikkelen seier vel inget annet en att fase 3 studien pågår. Men det som er sagt er att de kommer att søke en CTA på den
dokumentasjon de har hittils i studien. Og det skjer i mai, og blir den godkjent vilket tar ca 40 dag. Så kan de begynne behandle
pasienter i høst. De kan se resultatet av en cevira behandling med stor sikkerhet efter 6 mån, så de vet nok i dag hvor godt den
virker. Men hvor mye en godkjent CTA utløser av de 14 mil usd er eg usikker på, men det bør vare minst en 3 del.

Og det er jo en utroligt enkel behandling 10 min, og helt uten noen investeringer. Så fungerer den og priset ikke er avskrekkende
Så kommer den bli enormt mye brukt. Og fungerer den i Kina så fungerer den i USA og Europa og.
Det beste av alt er att det fungerer like bra med eller uten Schneider. De kommer aldri bruke han eller hans kostnadskrevende
salgsteknik før att få cevira på markedet. Så blir det godkjent i juni så er det meste gjort.

Dette er jo veldig lovende og egentlig litt merkelig at ikke PHO lagercen egen melding som beskriver den videre prosessen - svært store verdier i denne utviklingen

Hva får Pho utbetalt i år hvis denne godkjenningen faller på plass?

"Single digit million USD"

CTA i mai (?) ifølge Q4 presentasjonen.

Her kan det bli store utbetalinger

Kina våkner svært raskt ...

Tru om Spettet med Hegnar har planer om nye innlegg med aksjekjøp, ligger jo penger i slike flotte innlegg: )

Innleggene har nok ikke så stor verdi, men utbetaling på nærmere 100 mill rett på bunnlinjen kan jo gjøre inntrykk

Det gjelder å ikke vingle for mye i slike tider. Løpe etter aksjer som går til fordel for f.eks. PHO. Jeg tror ikke året vil bli så ille som pessimistene spår. PHO burde være noe av det sikreste å sitte med, selvom systoskopiske undersøkelser kan bli utsatt noe på grunn av corona-situasjonen. 35.000 er døde så langt av corona.
9.000.000 døde av kreft i 2015.

Et meget godt poeng - de underliggende prosessene er bunnsolide med mange positive muligheter. Samarbeidet med kineserne er mulighetsorientert